For the millions living with hearts that struggle despite the best medicines modern cardiology can offer, a small daily pill called AZD5462 has offered a quiet but meaningful signal of hope. Presented this week at the European Society of Cardiology Congress, results from the LUMINARA trial suggest that this oral relaxin agonist can improve cardiac function as an add-on to existing therapies — and, counterintuitively, that less may be more, with the lowest dose proving most effective in the sickest patients. The drug's origins trace back to a pregnancy hormone long admired for its vessel-relaxi